Methylprednisolone
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Methylprednisolone: Alopecia mucinosa
One-Sentence Summary
Methylprednisolone is a synthetic glucocorticoid (corticosteroid) that is marketed in India as tablets and injections. The TxGNN model predicts it may be useful for alopecia mucinosa, with a score of 0.9999. This is a model prediction only: the data compiled for this report contain 0 clinical trials and 0 publications on this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for methylprednisolone are not available in the data compiled for this report. As a glucocorticoid, it is generally understood to suppress inflammatory and immune activity. This is background knowledge, not a finding from the current data.
Alopecia mucinosa is an inflammatory disorder of the hair follicle. The model’s high score appears to reflect its closeness to other inflammatory hair-follicle conditions. A systemic anti-inflammatory drug could plausibly help in such a setting.
No trial or publication in the compiled data tests this idea. The link is hypothetical and should not be treated as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Methylprednisolone is marketed in India. Twenty valid single-ingredient licences are recorded, and the records may be partial. Oral tablets and injectable vials are both available. The first five licences are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 122866 | Linipred 4mg Tablet | Strip of 10 tablets | Not listed |
| 106151 | HB Meth 1gm Injection | Vial of 1 injection | Not listed |
| 151297 | Neo-Drol 500mg Injection | Vial of 1 ml injection | Not listed |
| 150821 | Neo-Drol 40mg Injection | Vial of 1 injection | Not listed |
| 129957 | Lumi M 16mg Tablet | Strip of 10 tablets | Not listed |
Safety Considerations
- Drug Interactions: 688 interactions are recorded. The main ones in the data are:
- Major: bupropion, clarithromycin.
- Moderate: several diabetes medicines (acarbose, metformin, pioglitazone, alogliptin, canagliflozin, dapagliflozin, empagliflozin, dulaglutide, albiglutide, saxagliptin, chlorpropamide), amphotericin B, aspirin, aprepitant, and the laxatives bisacodyl and picosulfuric acid.
- Minor: zinc sulfate.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score but no supporting trials or publications. The evidence level is therefore L5, and the proposed benefit is hypothetical.
To proceed, the following is needed:
- Clinical or observational evidence in alopecia mucinosa itself, such as case series or controlled studies.
- Detailed mechanism-of-action data for the drug.
- Package insert warnings and contraindications, which are not yet captured.
- A plan for route and dose, for example topical, intralesional or systemic, and a risk-benefit assessment for long-term corticosteroid use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.